Disease spectrum of abnormal serum free light chain ratio and its diagnostic significance.

about

Disease spectrum of abnormal serum free light chain ratio and its diagnostic significance.

Item

http://www.wikidata.org/entity/Q47098001

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Disease spectrum of abnormal s ...... d its diagnostic significance.

@en

Disease spectrum of abnormal s ...... d its diagnostic significance.

@nl

type

Item

label

Disease spectrum of abnormal s ...... d its diagnostic significance.

@en

Disease spectrum of abnormal s ...... d its diagnostic significance.

@nl

prefLabel

Disease spectrum of abnormal s ...... d its diagnostic significance.

@en

Disease spectrum of abnormal s ...... d its diagnostic significance.

@nl

P1476

Disease spectrum of abnormal s ...... d its diagnostic significance.

@en

P2093

Bin Xu

http://www.w3.org/2001/XMLSchema#string

Huijun Li

http://www.w3.org/2001/XMLSchema#string

Jianfeng Zhou

http://www.w3.org/2001/XMLSchema#string

Peiling Zhang

http://www.w3.org/2001/XMLSchema#string

Yi Tang

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains

Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management.

Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.

Value of serum free light chain testing for the diagnosis and monitoring of monoclonal gammopathies in hematology.

Screening panels for detection of monoclonal gammopathies.

Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.

Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.

MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.

P304

82268-82279

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.19391

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29137262

http://www.w3.org/2001/XMLSchema#string

P932

5669888

http://www.w3.org/2001/XMLSchema#string